However, the biological mechanisms and clinical significance in gastric DLBCL, due to resistance to eradication therapy through the mTOR pathway, are different from those of nodal DLBCL, due to cytokine production. The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.